摘要
目的评价新辅助化疗的疗效和在骨肉瘤保肢手术方面的作用。方法2001年9月～2005年4月治疗53例肢体骨肉瘤患者。化疗方案:异环磷酰胺2.0g/m2,第1～5天;甲氨蝶呤8g/m2,第3天;表柔吡星60mg/m2,第5天。每3～4周重复1次。评价化疗反应和化疗毒性。术前化疗3次,术后化疗6次。结果2例患者死于化疗毒性反应。完全缓解(CR)23例,部分缓解(PR)15例、稳定(SD)9例、进展(PD)5例。44例患者进行保肢手术,8例进行截肢。3年生存率为77.36%。结论异环磷酰胺、甲氨蝶呤、表柔吡星联合化疗方案有利于保肢手术,改善患者的预后,可以作为一种较理想的化疗方案。
Objective To retrospectively evaluate the efficacy and role ofneoadjuvant chemotherapy for osteosarcoma with ifosfamide, methotrexate and epirubicin in limb salvage surgery. Methods Fifty-three patients with osteosarcoma were consecutively treated from September, 2001 to April, 2005 with neoadjuvant chemotherapy based on ifosfamide 2.0g/m^2/day on days 1 to 5, methotrexate 8g/m^2/day on day 3 and epirubicin 60mg/m^2 on day 5. Repeated again every three to four weeks. Three times of chemotherapy and six times of chemotherapy were carried out before and after operation. Evaluation of objective tumor response and 3-year survival rate was carried out according to WHO criteria. Results Two patients died of toxicity. There were complete response in 23 patients, partial response in 15 patients, stable disease in 9 patients, and progress disease in 5 patients. The treatment was generally well-tolerated. Forty-four patients underwent limb salvage surgery, eight patients underwent amputation surgery. Three-year survival rate is 77.36%. Conclusions This therapeutic approach seems to be effective in facilitating limb salvage surgery and improve prognosis.
出处
《中国骨肿瘤骨病》
2008年第6期321-324,共4页
Chinse Journal Of Bone Tumor And Bone Disease
关键词
骨肉瘤
新辅助化疗
保肢手术
Osteosarcoma
Neoadjuvant chemotherapy
Limb salvage surgery
